Novartis (NVS)
(Delayed Data from NYSE)
$118.50 USD
-2.39 (-1.98%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $118.50 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.50 USD
-2.39 (-1.98%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $118.50 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum D VGM
Zacks News
Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business
by Zacks Equity Research
Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.
Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug
by Zacks Equity Research
Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.
Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies
by Zacks Equity Research
Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.
Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
by Zacks Equity Research
Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.
Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung
by Zacks Equity Research
Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.
Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs
by Kinjel Shah
FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).
Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion
by Zacks Equity Research
The FDA approves Novartis' (NVS) Cosentyx for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis.
Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA
by Zacks Equity Research
Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.
Novartis (NVS) Collaborates With BeiGene for Oncology Drug
by Zacks Equity Research
Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.
Ionis (IONS) Collaborates With AstraZeneca for Eplontersen
by Zacks Equity Research
Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the rest of the world.
Novartis (NVS) Highlights Growth Profile at its R&D Day
by Zacks Equity Research
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
Aurinia (AUPH) Stock Up on Potential Acquisition Rumors
by Zacks Equity Research
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs
by Zacks Equity Research
Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.
Bristol Myers' (BMY) Plaque Psoriasis Drug Filings Get Through
by Zacks Equity Research
Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Ligand's (LGND) Drug-Developing Technologies Holds Potential
by Zacks Equity Research
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.
Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST
by Zacks Equity Research
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021
Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab
by Kinjel Shah
Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021. Stock down.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Visa, Novartis, Advanced Micro Devices and Deere
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Visa, Novartis, Advanced Micro Devices and Deere
Q3 Earnings Scorecard & Analyst Reports for Berkshire Hathaway, Visa & Novartis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Visa Inc. (V), and Novartis AG (NVS).
Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.
Company News for Oct 27, 2021
by Zacks Equity Research
Companies in The news Are: UPS,WM,ARCC,NVS